Trial Profile

A Phase 2a Proof-of-Concept Study of GRX-917 for the Treatment of Mood Disorders

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etifoxine deuterated (Primary)
Indications Anxiety; Depression; Mood disorders
Focus Proof of concept; Registrational; Therapeutic Use
Sponsors ATAI Life Sciences

Most Recent Events

06 Mar 2023 According to a ATAI Life Sciences media release, this trial is conducted to generate the robust clinical data needed to inform a potential future registration.
09 Jan 2023 According to a ATAI Life Sciences media release, initiation of a GRX-917 efficacy study is anticipated in H1 2023 with results expected in 2024.
30 Mar 2022 According to a ATAI Life Sciences media release, initiation of the study is expected in 2H 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com